2,8-DIMETHYL-5,6,7,8-TETRAHYDRO-[1,2,4]TRIAZOLO[1,5-A]PYRAZINE, 95.0%, 250mg

6-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine, 95.0%, 5g

TAZEMETOSTAT, 98%, 250mg

α-Furil dioxime, 98%, 1g

2-({1-[(5-methyl-1,2-oxazol-3-yl)carbamoyl]ethyl}sulfanyl)acetic acid, 97%, 100mg

MCC950 sodium, 500mg

Fmoc-L-Glutamic Acid-(OtBu) Monohydrate, 5g, >=99%, for Biochemistry, Glass Packaging

1-[(2R,3S,4R,5R)-3,4-bis(benzoyloxy)-2-[(benzoyloxy)methyl]-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-2-yl]triaz-2-yn-2-ium-1-ide, 97%, 1g

methyl 2-methyl-3-[(3-methylbutan-2-yl)amino]propanoate, 95.0%, 2g

1-(1H-Indazol-4-yl)ethanone, 95.0%, 5g

4-(sec-Butyl)aniline, 95.0%, 100g

5-Bromo-6-methoxy-1H-indazole, 95.0%, 1g

(4-(BIS(4-CHLOROPHENYL)METHYL)PIPERAZIN-1-YL)(5-METHYL-4-NITROISOXAZOL-3-YL)METHANONE, 95%, 100mg